Naloxone Effects Against Cutaneous Leishmaniasis Caused by

Area of Science:

• Infectious Diseases
• Parasitology
• Pharmacology

Background:

• Cutaneous leishmaniasis (CL) poses a significant global health challenge, particularly in regions like Iran.
• Current treatments, such as meglumine antimoniate (MA), are associated with adverse side effects.
• There is a need for novel and safer therapeutic agents for CL management.

Purpose of the Study:

• To investigate the efficacy of naloxone as a potential treatment for cutaneous leishmaniasis.
• To evaluate the impact of naloxone on lesion size and parasite burden in a mouse model of Leishmania major infection.

Main Methods:

• BALB/c mice were infected with Leishmania major.
• Mice were divided into four groups: positive control (MA), negative control (PBS), and two naloxone treatment groups (daily and weekly SC injections).
• Lesion size was measured, and parasite burden was assessed post-treatment.

Main Results:

• Both meglumine antimoniate (MA) and naloxone treatments significantly reduced parasite burden compared to the negative control.
• Naloxone treatment resulted in significantly smaller lesion sizes compared to the negative control group.
• The efficacy of naloxone in reducing lesion size was comparable to that of MA.

Conclusions:

• Naloxone demonstrates potential as an effective and alternative therapeutic option for cutaneous leishmaniasis.
• Further research is warranted to explore naloxone's therapeutic role in CL treatment.